Literature DB >> 7964855

Experience with intravenous immunoglobulin in myasthenia gravis: a review.

G Edan1, F Landgraf.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7964855      PMCID： PMC1016727          DOI： 10.1136/jnnp.57.suppl.55

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  11 in total

Review 1.  Treatment of acquired autoimmune myasthenia gravis: a topic review.

Authors:  P Verma; J Oger
Journal:  Can J Neurol Sci       Date:  1992-08       Impact factor: 2.104

Review 2.  Manipulating the immune system with immune globulin.

Authors:  J M Dwyer
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

3.  High-dose intravenous immunoglobulin in the management of myasthenia gravis.

Authors:  E L Arsura; A Bick; N G Brunner; T Namba; D Grob
Journal:  Arch Intern Med       Date:  1986-07

4.  Immediate effects of intravenous IgG administration on peripheral blood B and T cells and polymorphonuclear cells in patients with myasthenia gravis.

Authors:  L Cook; J F Howard; J D Folds
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

5.  Aseptic meningitis as complication of intravenous immunoglobulin therapy for myasthenia gravis.

Authors:  Z Meiner; T Ben-Hur; Y River; A Reches
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-07       Impact factor: 10.154

Review 6.  Strategies for treatment of myasthenia gravis.

Authors:  D B Drachman; K R McIntosh; J Reim; L Balcer
Journal:  Ann N Y Acad Sci       Date:  1993-06-21       Impact factor: 5.691

7.  Therapies for exacerbation of myasthenia gravis. The mechanism of action of intravenous high-dose immunoglobulin G.

Authors:  B Ferrero; L Durelli; R Cavallo; A Dutto; G Aimo; F Pecchio; B Bergamasco
Journal:  Ann N Y Acad Sci       Date:  1993-06-21       Impact factor: 5.691

8.  High-dose intravenous gammaglobulin for myasthenia gravis.

Authors:  P Gajdos; H Outin; D Elkharrat; D Brunel; P de Rohan-Chabot; J C Raphael; M Goulon; C Goulon-Goeau; E Morel
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

9.  Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis.

Authors:  E L Arsura; A Bick; N G Brunner; D Grob
Journal:  Am J Med Sci       Date:  1988-05       Impact factor: 2.378

10.  Treatment of myasthenia gravis with high-dose intravenous immunoglobulin.

Authors:  V Cosi; M Lombardi; G Piccolo; A Erbetta
Journal:  Acta Neurol Scand       Date:  1991-08       Impact factor: 3.209
View more
  5 in total

1.  Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism.

Authors:  G DelGiudice-Asch; L Simon; J Schmeidler; C Cunningham-Rundles; E Hollander
Journal:  J Autism Dev Disord       Date:  1999-04

Review 2.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 3.  Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.

Authors:  Melvin Berger; Daniel E McCallus; Cindy Shin-Yi Lin
Journal:  J Peripher Nerv Syst       Date:  2013-12       Impact factor: 3.494

4.  VNTR2/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis.

Authors:  Shengyao Su; Qing Liu; Xueping Zhang; Xinmei Wen; Lin Lei; Faxiu Shen; Zhirong Fan; Jianying Duo; Yan Lu; Li Di; Min Wang; Hai Chen; Wenjia Zhu; Min Xu; Suobin Wang; Yuwei Da
Journal:  Ther Adv Neurol Disord       Date:  2021-01-27       Impact factor: 6.570

Review 5.  Current Treatment of Myasthenia Gravis.

Authors:  Mohammed K Alhaidar; Sumayyah Abumurad; Betty Soliven; Kourosh Rezania
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.